Mineralys Therapeutics, Inc.(MLYS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MLYS Mineralys Therapeutics, Inc.

Trading 03-18 13:23:01 EDT

24.40

-0.62

-2.48%

High24.53	Low23.60	Vol1.55M
Open24.53	D1 Closing25.02	Amplitude3.72%
Mkt Cap2.01B	Tradable Cap1.48B	Total Shares82.40M
T/O36.98M	T/O Rate2.56%	Tradable Shares60.57M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MLYS","market":"US","secType":"STK","nameCN":"Mineralys Therapeutics, Inc.","latestPrice":24.4,"timestamp":1773854576454,"preClose":25.02,"halted":0,"volume":1551276,"delay":0,"changeRate":-0.02478017585931259,"floatShares":60570600,"shares":82399500,"eps":-2.29,"marketStatus":"Trading","change":-0.62,"latestTime":"03-18 13:23:01 EDT","open":24.53,"high":24.53,"low":23.6,"amount":36983204.785656005,"amplitude":0.03717,"askPrice":24.48,"askSize":34,"bidPrice":24.38,"bidSize":42,"shortable":3,"etf":0,"ttmEps":-2.29,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1773864000000},"marketStatusCode":2,"adr":0,"listingDate":1676005200000,"exchange":"NASDAQ","adjPreClose":25.02,"preHourTrading":{"tag":"盘前","latestPrice":25.91,"preClose":25.02,"latestTime":"09:29 EDT","volume":212,"amount":5286.6698639999995,"timestamp":1773840585054,"change":0.89,"changeRate":0.035572,"amplitude":0.061151},"postHourTrading":{"tag":"盘后","latestPrice":25.02,"preClose":25.02,"latestTime":"16:39 EDT","volume":51590,"amount":1290780.84,"timestamp":1773779976620,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":2.209244,"impliedVol":0.8453,"impliedVolPercentile":0.51},"requestUrl":"/m/hq/s/MLYS/tweets","defaultTab":"tweets","newsList":[{"id":"2620492319","title":"Mineralys CMO David Malcom Rodman disposes of USD 557,000 in common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2620492319","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620492319?lang=en_us&edition=fundamental","pubTime":"2026-03-17 05:20","pubTimestamp":1773696050,"startTime":"0","endTime":"0","summary":"David Malcom Rodman, Chief Medical Officer, reported a disposal of common shares of Mineralys Therapeutics.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mineralys Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 16, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDL64nQ70:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Mineralys CMO David Malcom Rodman disposes of USD 557,000 in common shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLYS"],"gpt_icon":0},{"id":"2620749447","title":"BRIEF-Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620749447","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620749447?lang=en_us&edition=fundamental","pubTime":"2026-03-17 05:05","pubTimestamp":1773695124,"startTime":"0","endTime":"0","summary":"BRIEF-Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)March 16 (Reuters) - Mineralys Therapeutics Inc MLYS.O:MINERALYS THERAPEUTICS REPORTS INDUCEMENT AWARDS UNDER","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nTUABMZSCV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLYS"],"gpt_icon":0},{"id":"2620499912","title":"Mineralys Therapeutics grants inducement equity awards covering 48,860 shares under 2025 plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2620499912","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620499912?lang=en_us&edition=fundamental","pubTime":"2026-03-17 04:09","pubTimestamp":1773691758,"startTime":"0","endTime":"0","summary":"Mineralys reported inducement equity awards under its 2025 Employment Inducement Incentive Award Plan for a new non-executive employee. The company granted a stock option covering 27,920 shares and restricted stock units covering 20,940 shares. The stock option vests over four years, with 25% vesting after one year and the remainder vesting monthly thereafter. The restricted stock units vest over four years, with 25% vesting on each annual anniversary.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDL1z4zGf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","LU2095319765.USD","LU0314104364.USD","BK4139","IE00BGHQF748.EUR","SG9999014039.USD","LU2210150020.SGD","SG9999014013.SGD","SG9999014005.SGD","IE00BN0W2V16.EUR","BK4585","SG9999014021.USD","LU2210149790.SGD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","BK4112","NDAQ","IE00BN0W2T93.GBP","MLYS","IE00BN0W2W23.USD","BK4588"],"gpt_icon":0},{"id":"2620460826","title":"Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS) and Aprea Therapeutics (APRE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620460826","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620460826?lang=en_us&edition=fundamental","pubTime":"2026-03-17 00:40","pubTimestamp":1773679205,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Mineralys Therapeutics, Inc. (MLYS – Research Report...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-mineralys-therapeutics-inc-mlys-and-aprea-therapeutics-apre-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-mineralys-therapeutics-inc-mlys-and-aprea-therapeutics-apre-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","BK4585","BK4588","LU0029874061.USD","MLYS","XBI","XLV","APRE","BK4581","BK4139","LU0128526141.USD","HCSG","LABU"],"gpt_icon":0},{"id":"2619227581","title":"Mineralys Therapeutics, Inc. (MLYS) Receives a Buy from Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2619227581","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619227581?lang=en_us&edition=fundamental","pubTime":"2026-03-15 00:36","pubTimestamp":1773506171,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Buy rating on Mineralys Therapeutics, Inc., with a price target of $55.0...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/mineralys-therapeutics-inc-mlys-receives-a-buy-from-wells-fargo-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/mineralys-therapeutics-inc-mlys-receives-a-buy-from-wells-fargo-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0314106906.USD","IE00B19Z3581.USD","LU0149725797.USD","MLYS","LU0310800965.SGD","LU0208291251.USD","LU0175139822.USD","LU0251131958.USD","BK4588","LU0154236417.USD","LU0128525929.USD","LU1267930573.SGD","LU0251142724.SGD","LU1363072403.SGD","IE000M9KFDE8.USD","LU2361044865.SGD","LU0128525689.USD","LU1668664300.SGD","LU0070302665.USD","LU0942090050.USD","LU0648001328.SGD","BK4207","LU1201861249.SGD","LU0267386448.USD","LU2461242641.AUD","LU1267930227.SGD","LU0310799852.SGD","IE00B19Z3B42.SGD","LU2361044949.HKD","LU1506573853.SGD","LU1069347547.HKD","LU1280957306.USD","LU0256863811.USD","LU0320765489.SGD","LU0708994859.HKD","LU1814569148.SGD","LU0072461881.USD","LU0029864427.USD","LU0106831901.USD","LU0742534661.SGD","LU0787776722.HKD","LU0052756011.USD","LU0640476718.USD","BK4139","BK4501","IE0002270589.USD","LU1035773651.USD","LU0162691827.USD","LU0477156953.USD","LU0048573561.USD"],"gpt_icon":0},{"id":"1154474290","title":"Stock Track | Mineralys Therapeutics Soars 5.26% Intraday on Bank of America's Buy Rating Reiteration","url":"https://stock-news.laohu8.com/highlight/detail?id=1154474290","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154474290?lang=en_us&edition=fundamental","pubTime":"2026-03-13 21:48","pubTimestamp":1773409708,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics, Inc. (MLYS) saw its stock price surge 5.26% during intraday trading on Friday, marking a significant upward movement for the biopharmaceutical company.The price increase...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["MLYS"],"gpt_icon":0},{"id":"2619194575","title":"Bank of America Securities Sticks to Their Buy Rating for Mineralys Therapeutics, Inc. (MLYS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2619194575","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619194575?lang=en_us&edition=fundamental","pubTime":"2026-03-13 19:56","pubTimestamp":1773402989,"startTime":"0","endTime":"0","summary":"Bank of America Securities analyst Jason Gerberry reiterated a Buy rating on Mineralys Therapeutics, Inc. yesterday and set a price target of $51.0...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bank-of-america-securities-sticks-to-their-buy-rating-for-mineralys-therapeutics-inc-mlys-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bank-of-america-securities-sticks-to-their-buy-rating-for-mineralys-therapeutics-inc-mlys-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MLYS","BAC"],"gpt_icon":0},{"id":"2619155241","title":"Mineralys Therapeutics Q4 Loss Narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2619155241","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619155241?lang=en_us&edition=fundamental","pubTime":"2026-03-13 04:14","pubTimestamp":1773346469,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics  reported a Q4 loss late Thursday of $0.40 per diluted share, narrowing from a loss of $0.98 a year earlier.Analysts polled by FactSet expected a loss of $0.52.As of Dec. 31, the company had cash and cash equivalents of $656.6 million, expected to be adequate to fund its planned clinical trials and support corporate operations through 2028.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","BK4139","BK4539","BK4007","MLYS"],"gpt_icon":0},{"id":"2619155210","title":"Earnings Flash (MLYS) Mineralys Therapeutics Posts Q4 Loss of $0.40, vs. FactSet Est of $0.52 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2619155210","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619155210?lang=en_us&edition=fundamental","pubTime":"2026-03-13 04:12","pubTimestamp":1773346372,"startTime":"0","endTime":"0","summary":"Earnings Flash (MLYS) Mineralys Therapeutics Posts Q4 Loss of $0.40, vs. FactSet Est of $0.52 Loss","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MLYS"],"gpt_icon":0},{"id":"2618447969","title":"Mineralys Therapeutics Inc  expected to post a loss of 53 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2618447969","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618447969?lang=en_us&edition=fundamental","pubTime":"2026-03-11 04:32","pubTimestamp":1773174725,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics Inc  expected to post a loss of53cents a share - Earnings Preview Mineralys Therapeutics Inc MLYS.OQ MLYS.O is expected to  show no change in quarterly revenue when it reports  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nL8N3ZY2KZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLYS"],"gpt_icon":0},{"id":"2618608703","title":"Mineralys Therapeutics' Treatment Fails to Reduce Sleep Apnea","url":"https://stock-news.laohu8.com/highlight/detail?id=2618608703","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618608703?lang=en_us&edition=fundamental","pubTime":"2026-03-10 07:14","pubTimestamp":1773098040,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics said its drug lorundrostat didn't meaningfully reduce sleep apnea in a Phase 2 trial.The biopharmaceutical company said Monday that the treatment didn't demonstrate a reduction in the Apnea-Hypopnea Index, which measures the number of times breathing stops or becomes shallow during an hour of sleep.Shares fell 3%, to $26.35, in after-hours trading.Lorundrostat did show meaningful reductions in blood pressure and had a meaningful safety profile, Chief Executive Jon Congleton said.The trial involved 48 patients and lasted four weeks.The Radnor, Pa., company also said the Food and Drug Administration accepted the new drug application for lorundrostat for the treatment of adult patients with hypertension in combination with other antihypertensive drugs.The FDA has assigned a Prescription Drug User Fee Act target action date of Dec. 22.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4539","BK4007","MLYS","BK4139"],"gpt_icon":0},{"id":"2618672888","title":"FDA accepts Mineralys Therapeutics’ lorundrostat NDA with Dec. 22, 2026 PDUFA date","url":"https://stock-news.laohu8.com/highlight/detail?id=2618672888","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618672888?lang=en_us&edition=fundamental","pubTime":"2026-03-10 04:30","pubTimestamp":1773088234,"startTime":"0","endTime":"0","summary":"The FDA accepted Mineralys Therapeutics’ NDA for lorundrostat to treat adults with hypertension in combination with other antihypertensive drugs. The agency set a PDUFA target action date of December 22, 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nNDL8Q95w1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","SG9999014013.SGD","IE00BKPKM429.USD","SG9999014005.SGD","LU2210150020.SGD","IE00B3QW5Z07.USD","BK4112","MLYS","IE00B64PRP62.GBP","NDAQ","SG9999014039.USD","BK4588","SG9999014021.USD","BK4139","BK4585","LU2095319765.USD","IE00BGHQF748.EUR","LU0314104364.USD"],"gpt_icon":0},{"id":"2618740086","title":"Mineralys Therapeutics Inc - FDA Assigns Pdufa Target Action Date of December 22, 2026 for Lorundrostat Nda","url":"https://stock-news.laohu8.com/highlight/detail?id=2618740086","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618740086?lang=en_us&edition=fundamental","pubTime":"2026-03-10 04:30","pubTimestamp":1773088200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nTUA8QF4VN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MLYS"],"gpt_icon":0},{"id":"2618674071","title":"Mineralys Therapeutics Announces FDA Acceptance of Nda for Lorundrostat for Treatment of Adults With Hypertension and Topline Explore-Osa Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2618674071","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618674071?lang=en_us&edition=fundamental","pubTime":"2026-03-10 04:30","pubTimestamp":1773088200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nTUA8QF4VN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MLYS"],"gpt_icon":0},{"id":"2617980995","title":"Mineralys Therapeutics Files Initial Beneficial Ownership Statement for Chief Commercial Officer Eric Warren","url":"https://stock-news.laohu8.com/highlight/detail?id=2617980995","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617980995?lang=en_us&edition=fundamental","pubTime":"2026-03-05 08:25","pubTimestamp":1772670351,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics, Inc. filed an initial statement of beneficial ownership reporting holdings for Eric Warren, Chief Commercial Officer. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mineralys Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 04, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nNDL2F8mhd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLYS","BK4139"],"gpt_icon":0},{"id":"2616380793","title":"A Look At Mineralys Therapeutics (MLYS) Valuation As Lorundrostat Progress Shapes Investor Optimism","url":"https://stock-news.laohu8.com/highlight/detail?id=2616380793","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616380793?lang=en_us&edition=fundamental","pubTime":"2026-03-02 17:23","pubTimestamp":1772443400,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics (MLYS) has drawn fresh attention as investors react to progress on its lead candidate lorundrostat, with upcoming clinical data and a potential New Drug Application in 2026 influencing sentiment around the stock.\nSee our latest analysis for Mineralys Therapeutics.\nAt a share price of US$29.26, Mineralys has recently seen pressure, with a 30 day share price return of 5.28% decline and a 90 day share price return of 25.26% decline. However, the 1 year total shareholder...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mlys/mineralys-therapeutics/news/a-look-at-mineralys-therapeutics-mlys-valuation-as-lorundros","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mlys/mineralys-therapeutics/news/a-look-at-mineralys-therapeutics-mlys-valuation-as-lorundros","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","DCF","BK4097","MLYS","PRGS","LU2065732104.USD"],"gpt_icon":0},{"id":"2614076817","title":"Mineralys Therapeutics Reports Inducement Equity Awards Under Nasdaq Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2614076817","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614076817?lang=en_us&edition=fundamental","pubTime":"2026-02-27 05:07","pubTimestamp":1772140043,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics said its board compensation committee granted inducement equity awards to a new non-executive employee on Feb. 23, 2026, consisting of stock options covering 27,920 shares and restricted stock units covering 20,940 shares. The option vests over four years with 25% vesting after one year and the remainder vesting monthly thereafter, while the RSUs vest in four equal annual installments over four years. The awards were made under the company’s 2025 Employment Inducement Incentive Award Plan.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mineralys Therapeutics Inc. published the original content used to generate this news brief on February 26, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nNDL6pFMPb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLYS","BK4139"],"gpt_icon":0},{"id":"2612499799","title":"Mineralys Therapeutics Chief Medical Officer David Malcom Rodman Reports Common Share Disposal","url":"https://stock-news.laohu8.com/highlight/detail?id=2612499799","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612499799?lang=en_us&edition=fundamental","pubTime":"2026-02-18 07:57","pubTimestamp":1771372629,"startTime":"0","endTime":"0","summary":"David Malcom Rodman, Chief Medical Officer of Mineralys Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mineralys Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 17, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nNDL4CZk0B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Mineralys Therapeutics Chief Medical Officer David Malcom Rodman Reports Common Share Disposal","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLYS"],"gpt_icon":0},{"id":"2610960064","title":"Mineralys Therapeutics Grants Inducement Equity Awards to New Employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2610960064","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610960064?lang=en_us&edition=fundamental","pubTime":"2026-02-12 08:00","pubTimestamp":1770854451,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics Inc. has granted inducement stock option awards covering 33,504 shares and inducement restricted stock unit awards covering 25,128 shares of its common stock to two new non-executive employees. The stock options will vest over four years, with 25% vesting on the first anniversary of the vesting commencement date, February 9, 2026, and the remainder vesting in equal monthly installments thereafter. The restricted stock units will also vest over four years, with 25% vesting on each anniversary of the vesting commencement date. These awards were made under the company’s 2025 Employment Inducement Incentive Award Plan.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mineralys Therapeutics Inc. published the original c","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nNDLbJgBCT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","BK4588","IE00B3QW5Z07.USD","SG9999014021.USD","BK4112","BK4139","LU2210150020.SGD","BK4585","SG9999014013.SGD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","SG9999014039.USD","LU2210149790.SGD","SG9999014005.SGD","MLYS","IE00BKPKM429.USD","NDAQ","LU2095319765.USD"],"gpt_icon":0},{"id":"2610960029","title":"Press Release: Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2610960029","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610960029?lang=en_us&edition=fundamental","pubTime":"2026-02-12 08:00","pubTimestamp":1770854400,"startTime":"0","endTime":"0","summary":"RADNOR, Pa., Feb. 11, 2026  -- Mineralys Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease , obstructive sleep apnea  and other diseases driven by dysregulated aldosterone, announced today that on February 9, 2026, the Compensation Committee of Mineralys' Board of Directors granted inducement stock option awards covering 33,504 shares and inducement restricted stock unit awards covering 25,128 shares of Mineralys common stock to two new non-executive employees.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4539","NQmain","BK4139","MLYS","LENZ"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mineralystx.com;www.ir.mineralystx.com","stockEarnings":[{"period":"1week","weight":-0.1199},{"period":"1month","weight":-0.0935},{"period":"3month","weight":-0.3241},{"period":"6month","weight":-0.3725},{"period":"1year","weight":0.7595},{"period":"ytd","weight":-0.3106}],"compareEarnings":[{"period":"1week","weight":-0.0094},{"period":"1month","weight":-0.0161},{"period":"3month","weight":-0.0009},{"period":"6month","weight":0.0129},{"period":"1year","weight":0.1827},{"period":"ytd","weight":-0.0163}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.014493},{"month":2,"riseRate":0.333333,"avgChangeRate":0.081442},{"month":3,"riseRate":0.25,"avgChangeRate":0.078169},{"month":4,"riseRate":0,"avgChangeRate":-0.099137},{"month":5,"riseRate":1,"avgChangeRate":0.0733},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.014247},{"month":7,"riseRate":0.666667,"avgChangeRate":-0.022154},{"month":8,"riseRate":0.666667,"avgChangeRate":0.001437},{"month":9,"riseRate":0.333333,"avgChangeRate":0.388697},{"month":10,"riseRate":0.666667,"avgChangeRate":-0.001589},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.0429},{"month":12,"riseRate":0.333333,"avgChangeRate":0.032291}],"exchange":"NASDAQ","name":"Mineralys Therapeutics, Inc.","nameEN":"Mineralys Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Mineralys Therapeutics, Inc.(MLYS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Mineralys Therapeutics, Inc.(MLYS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Mineralys Therapeutics, Inc.,MLYS,Mineralys Therapeutics, Inc.股票,Mineralys Therapeutics, Inc.股票老虎,Mineralys Therapeutics, Inc.股票老虎国际,Mineralys Therapeutics, Inc.行情,Mineralys Therapeutics, Inc.股票行情,Mineralys Therapeutics, Inc.股价,Mineralys Therapeutics, Inc.股市,Mineralys Therapeutics, Inc.股票价格,Mineralys Therapeutics, Inc.股票交易,Mineralys Therapeutics, Inc.股票购买,Mineralys Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Mineralys Therapeutics, Inc.(MLYS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Mineralys Therapeutics, Inc.(MLYS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction